Skip to main content

A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants with Melanoma (KEYNOTE-U02): Substudy 02C

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

March 23, 2021

End Date

March 16, 2026
 

Administered By

Duke Cancer Institute

Awarded By

Merck Sharp & Dohme

Start Date

March 23, 2021

End Date

March 16, 2026